Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group (ISS).
Petrucci A, Dorrucci M, Alliegro MB, Pezzotti P, Rezza G, Sinicco A, Lazzarin A, Angarano G. Petrucci A, et al. Among authors: angarano g. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):243-8. doi: 10.1097/00042560-199703010-00008. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. PMID: 9117457
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K. Vella S, et al. Among authors: angarano g. Antivir Ther. 1996 Aug;1(3):129-40. Antivir Ther. 1996. PMID: 11322246 Clinical Trial.
Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?
Pezzotti P, d'Arminio Monforte A, Bugarini R, Rezza G, Arici C, Angarano G, Borderi M, Alberici F, Armignacco O, Menichetti F, Prestileo T, Sighinolfi L, Sinicco A, Resta F, Vigevani M, Ippolito G; ICONA Study Group. Italian Cohort of Naïve Antivirals. Pezzotti P, et al. Among authors: angarano g. Eur J Epidemiol. 2000;16(10):919-26. doi: 10.1023/a:1011054418761. Eur J Epidemiol. 2000. PMID: 11338123
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M. d'Arminio Monforte A, et al. Among authors: angarano g. AIDS. 2000 Mar 31;14(5):499-507. doi: 10.1097/00002030-200003310-00005. AIDS. 2000. PMID: 10780712 Clinical Trial.
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort.
d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, Castagna A, Passerini S, Francisci D, Saracino A, Maggiolo F, Lapadula G, Girardi E, Perno CF, Antinori A; Icona Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):681-689. doi: 10.1093/jac/dkz512. J Antimicrob Chemother. 2020. PMID: 31865395
Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy.
Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Angarano G, Arici C, Narciso P, Orani A, Raise E, Scalzini A, Poggio A, Ippolito G, Moroni M, Monforte AD; ICONA Study Group. Perno CF, et al. Among authors: angarano g. Antivir Ther. 2001 Sep;6(3):195-8. Antivir Ther. 2001. PMID: 11808755 No abstract available.
408 results